Tadalafil is under clinical development by United Laboratories International and currently in Phase I for Erectile Dysfunction. According to GlobalData, Phase I drugs for Erectile Dysfunction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tadalafil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tadalafil overview
Tadalafil is under development for the treatment of erectile dysfunction. The drug candidate is administered through oral route in the form of tablet. It acts by targeting phosphodiesterase type 5 (PDE5).
United Laboratories International overview
United Laboratories International (United Lab) is a pharmaceutical company that manufactures and sells pharmaceutical products. The company offers products through divisions such as preparation products, intermediate products, capsule products, raw material products, and health products. It also provides antibiotics, pharmaceutical raw materials and intermediates, material products and healthcare products. United Laboratories’ drug products include amoxicillin capsules, ampicillin capsules, clavulana capsules, levofloxacin hydrochlorid, and cefuroxime axetil tablets, among others. It sells its products through a network of distributors in Europe, North America, East Africa and southeast Asia. United Lab is headquartered in Yuen Long, Hong Kong.
For a complete picture of Tadalafil’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
